Semaglutide in Nonalcoholic Fatty Liver Disease

What this study is testing ClinicalTrials.gov NCT05813249 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to test the therapeutic effect of Semaglutide in NAFLD and its sequelae in obesity and/or type 2 diabetes mellitus. The main question it aims to answer is: • Is the use of Semaglutide (oral or subcutaneous form) effective in improving NAFLD and its sequelae in obesity and/or type 2 diabetes mellitus? Participants will undergo: * Abdominal ultrasound. * Fibroscan with controlled attenuation parameter to assess liver stiffness (kPa) and liver steatosis (dB/m). * Fibrosis-4 score requires values of age, alanine aminotransferase, aspartate aminotransferase, and platelet count. * NAFLD Fibrosis Score requires values of age, BMI, platelet count, albumin, hyperglycemia, and ALT/AST ratio. Researchers will compare: * Group 1 will receive oral Semaglutide for 48 weeks. * Group 2 will receive injectable Semaglutide for 48 weeks. * Group 3 will receive Pioglitazone and/or Vitamin E. to see if there is an improvement in liver stiffness and severity of hepatic steatosis after 48 weeks.

Treatments tested

• Rybelsus Oral Product Drug

  Oral Semaglutide

• Ozempic Injectable Product also known as Wegovy Drug

  Subcutaneous Semaglutide

• Tocopherol and/or Actos Drug

  Vitamin E and/or Pioglitazone